Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

M3 Biotechnology

M3 Biotechnology
2011 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series B LATEST DEAL TYPE
$15.2M LATEST DEAL AMOUNT
10 INVESTORS
Description

Operator of a therapeutics company with a platform of novel disease-modifying regenerative small molecules being developed with the potential to stop disease progression and even restore lost function. M3 has advanced a lead candidate for Alzheimer's disease to first-in-human Phase I clinical trials assessing safety, toxicity and tolerability while also evaluating a novel biomarker for AD. The company's solutions act on trophic factors of a highly conserved mechanism of action. The core technology and lead candidate has the potential to address neurodegenerative therapies broadly. The company has optimized a lead compound for a first indication in AD, launched clinical trials and expanded the therapeutics pipeline.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • CoMotion Labs Fluke Hall 4000 Mason Road
  • Suite 300, Box 352141
  • Seattle, WA 98195-2141
  • United States

+1 (206) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore M3 Biotechnology’s full profile, request a free trial.

M3 Biotechnology Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 13-Oct-2017 $15.2M 000.00 Completed Clinical Trials - Phase 1
4. Later Stage VC 13-Apr-2017 00.00 000.00 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 11-Feb-2016 0000 0000 Completed Pre-Clinical Trials
2. Seed Round 19-Sep-2014 $1M $1M Completed Startup
1. Grant $750K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

M3 Biotechnology Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Kayne Anderson Capital Advisors PE/Buyout Minority 000 0000 000000 0
Bruce Montgomery Angel (individual) Minority 000 0000 000000 0
Michael Montgomery Angel (individual) Minority 000 0000 000000 0
The W Fund Venture Capital Minority 000 0000 000000 0
WRF Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

M3 Biotechnology Executive Team (10)

Name Title Board
Seat
Contact
Info
Leen Kawas Ph.D Chief Executive Officer, Founder, Board of Director & President
Glenna Mileson Chief Financial Officer, Board Member & Corporate Secretary
Joseph Harding Ph.D Chief Scientific Officer & Board Member
Josh Pan Ph.D Director of Business Development
Bassem Bejjani MD Advisor, Business and Strategy
You’re viewing 5 of 10 executives. Get the full list »

M3 Biotechnology Board Members (6)

Name Representing Role Since Contact
Info
Bruce Montgomery MD Self Board Member 000 0000
Glenna Mileson M3 Biotechnology Chief Financial Officer, Board Member & Corporate Secretary 000 0000
John Fluke Jr. Self Chairman 000 0000
Joseph Harding Ph.D M3 Biotechnology Chief Scientific Officer & Board Member 000 0000
Lance Stewart Ph.D Self Chairman & Advisor 000 0000
You’re viewing 5 of 6 board members. Get the full list »